Key highlights
- Confirmed objective response rate reached 39% among 33 efficacy-evaluable patients
- Median progression-free survival recorded at 6.7 months as of October 2026
- Overall survival probability at 12 months estimated at 81% for the study cohort
- Median duration of response stood at 9.2 months, highlighting durable clinical benefit
- Safety data showed no new cases of Grade 3 peripheral neuropathy under new dose-capping protocols
Clinical Trial Advancements
Pyxis Oncology presented updated results from its global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) at the EORTC-NCI-AACR Symposium. The data, updated as of October 14, 2026, focused on patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. Results showed deep and durable responses, including a 94% disease control rate. Notably, a novel analysis revealed that MICVO increased median progression-free survival by 50% compared to the most recent prior therapies received by the participants. The company also highlighted improved safety outcomes through effective dose-capping strategies designed for patients above specific weight thresholds.
Strategic Significance
- Clinical activity remained consistent across diverse subgroups, including HPV-positive and HPV-unrelated patients
- New safety protocols resulted in 83% of Grade 3 peripheral neuropathy cases resolving to Grade 1 or better
- The October update provides a definitive data profile to support the upcoming Phase 3 Headliner trial
- Company plans to initiate regulatory meetings in the near term to finalize late-stage development paths
- More mature overall survival data is anticipated in the first half of 2027 to further validate the drug profile
Business and Industry Context
Based in Boston, Pyxis Oncology is a clinical-stage biopharmaceutical company specialized in developing next-generation therapeutics, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Their lead ADC candidate, MICVO, leverages proprietary linker-payload technology to target difficult-to-treat cancers. The head and neck cancer market represents a significant unmet medical need for patients who fail platinum-based chemotherapy and immunotherapy. By demonstrating durable responses in these later-line settings, Pyxis is positioning itself within a high-growth oncology sector currently focused on ADC innovation to replace traditional chemotherapy regimens.
Financial Performance
- Pyxis Oncology currently carries a market capitalization of approximately $168.6 million on the NASDAQ Global Select Market
- The stock is trading with a 14-day Relative Strength Index of 30.2, indicating it is nearing oversold territory
- Annual revenue for the trailing twelve months stands at $13.858 million, reflecting the company's clinical-stage focus
- The company experienced a 53.3% share price decline over the last quarter amid broader biotech sector volatility
Up 28.4% since our story on 19 Nov: $1.41 when we broke it → $1.81 at the close on 20 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 21 Oct | $1.76 |
|---|---|
| 22 Oct | $1.71 |
| 23 Oct | $1.68 |
| 26 Oct | $1.69 |
| 27 Oct | $1.84 |
| 28 Oct | $1.98 |
| 29 Oct | $1.89 |
| 30 Oct | $1.81 |
| 2 Nov | $1.69 |
| 3 Nov | $1.64 |
| 4 Nov | $1.66 |
| 5 Nov | $1.61 |
| 6 Nov | $1.66 |
| 9 Nov | $1.70 |
| 10 Nov | $1.63 |
| 11 Nov | $1.64 |
| 12 Nov | $1.58 |
| 13 Nov | $1.58 |
| 16 Nov | $1.41 |
| 17 Nov | $1.44 |
| 18 Nov | $1.41 |
| 19 Nov | $1.68 |
| 20 Nov | $1.81 |
Management commentary
“The data from October show improvements across multiple key clinical activity endpoints with a novel analysis showing that MICVO increased mPFS by 50% versus the most recent prior therapy patients had received before MICVO. We are also very happy to report that our clinical strategy for managing safety has had the intended impact.”
| Share price | $1.41 |
|---|---|
| Market cap | $169M |
| Revenue (annual) | $14M |
| 1-month price change | -19.89% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Pyxis Oncology, Inc. announcing updated Phase 1 clinical data for MICVO and plans for a Phase 3 trial.
Track Pyxis Oncology, Inc. live
Get the next Pyxis Oncology, Inc. SEC filing seconds after it lands.